Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
Immunofluorescent analysis of CD227/MUC1/Mucin 1 (green) showing staining in the in the cytoplasm of T47D cells (right) compared to a negative control without primary antibody (left). Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with a CD227/MUC1/Mucin 1 monoclonal antibody (Product # MA5-11202) in 3% BSA-PBS at a dilution of 1:50 and incubated overnight at 4°C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight-conjugated secondary antibody in PBS at room temperature in the dark. F-actin (red) was stained with a flourescent red phalloidin and nuclei (blue) were stained with Hoechst or DAPI. Images were taken at a magnification of 60x.
|Tested species reactivity||Human, Mouse|
|Published species reactivity||Rat, Human, Mouse|
|Host / Isotype||Armenian hamster / IgG|
|Immunogen||A synthetic peptide corresponding to aa 239-255 (SSLSYTNPAVAATSANL) from the cytoplasmic tail of MUC1|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||1-2 ug/test|
|Immunohistochemistry (Paraffin) (IHC (P))||1:10-1:100|
|Western Blot (WB)||1:10,000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (Paraffin) (IHC (P))||See 2 publications below|
|ChIP assay (ChIP)||See 4 publications below|
|Immunohistochemistry (IHC)||See 9 publications below|
|Western Blot (WB)||See 12 publications below|
|Immunoprecipitation (IP)||See 4 publications below|
|Immunocytochemistry (ICC)||See 4 publications below|
MA5-11202 detects smaller subunits (14-28kDa) of MUC-1.
Muc-1 is overexpressed in Breast cancer cells.
T47D cell lysate could be used as a positive control.
Muc1 is a heavily O-glycosylated transmembrane protein expressed on most secretory epithelium, including mammary gland and some hematopoietic cells. It is expressed abundantly in lactating mammary glands and overexpressed in >90% breast carcinomas and metastases. In normal mammary gland it is expressed in apical surface of glandular epithelium. In breast cancer Muc1 is overexpressed; is underglycosylated and the apical localization is lost. Muc1 is transcribed as a larger precursor which is cleaved to form a larger mucin like subunit (265-400kDa) and a smaller subunit (14-28kDa) noncovalently associated with each other. Transgenic Muc1 has been shown to associate with all four erbB receptors and localize with erbB1 (EGFR) in lactating glands1. Muc1 can act as a ligand for ICAM-1 on HUVEC cells; it can bind beta-catenin, GSK3beta and it associates with Grb2-SOS upon phosphorylation.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells.
MA5-11202 was used in immunohistochemistry - paraffin section to determine if miRNA that target Muc1 are protective against pancreatic cancer
|Tréhoux S,Lahdaoui F,Delpu Y,Renaud F,Leteurtre E,Torrisani J,Jonckheere N,Van Seuningen I||Biochimica et biophysica acta (1853:2392)||2015|
Transcription factors SOX4 and SOX9 cooperatively control development of bile ducts.
MA5-11202 was used in immunohistochemistry - paraffin section to investigate the role of transcription factors SOX4 and SOX9 during the development of bile ducts
|Poncy A,Antoniou A,Cordi S,Pierreux CE,Jacquemin P,Lemaigre FP||Developmental biology (404:136)||2015|
MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition.
MA5-11202 was used in ChIP assay to study the role of oncogenic MUC1-c in modulating EB1 and miR-200c expression and in promoting epithelial-mesenchymal transition
|Rajabi H,Alam M,Takahashi H,Kharbanda A,Guha M,Ahmad R,Kufe D||Oncogene (33:1680)||2014|
Oncogenic MUC1-C promotes tamoxifen resistance in human breast cancer.
MA5-11202 was used in ChIP assay to study the mechanism by which the oncogenic MUC1-C subunit promotes human breast cancer tamoxifen resistance
|Kharbanda A,Rajabi H,Jin C,Raina D,Kufe D||Molecular cancer research : MCR (11:714)||2013|
Cooperative interaction between the MUC1-C oncoprotein and the Rab31 GTPase in estrogen receptor-positive breast cancer cells.
MA5-11202 was used in ChIP assay and western blot to study the interaction between MUC1-C and Rab 31 GTPase and its role in driving overexpression of MUC1-C in breast cancer cells
|Jin C,Rajabi H,Pitroda S,Li A,Kharbanda A,Weichselbaum R,Kufe D||PloS one (7:null)||2012|
MUC1-C oncoprotein induces TCF7L2 transcription factor activation and promotes cyclin D1 expression in human breast cancer cells.
MA5-11202 was used in ChIP assay and western blot to study the role of TCF7L2 activation in the mechanism by which oncogenic MUC1-C promotes human breast cancer cell cyclin D1 expression
|Rajabi H,Ahmad R,Jin C,Kosugi M,Alam M,Joshi MD,Kufe D||The Journal of biological chemistry (287:10703)||2012|
The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma.
MA5-11202 was used in immunohistochemistry to study the formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma and the suppressive role of the Brg1 component of chromatin remodeling complexes
|von Figura G,Fukuda A,Roy N,Liku ME,Morris Iv JP,Kim GE,Russ HA,Firpo MA,Mulvihill SJ,Dawson DW,Ferrer J,Mueller WF,Busch A,Hertel KJ,Hebrok M||Nature cell biology (16:255)||2014|
Elimination of von Hippel-Lindau function perturbs pancreas endocrine homeostasis in mice.
MA5-11202 was used in immunohistochemistry to study the effects of endocrine pancreatic deletion of von Hippel-Lindau factor on insulin and glucagon responses and glycemic homeostasis
|Puri S,García-Núñez A,Hebrok M,Cano DA||PloS one (8:null)||2013|
Canonical Notch2 signaling determines biliary cell fates of embryonic hepatoblasts and adult hepatocytes independent of Hes1.
MA5-11202 was used in immunohistochemistry to study the determination of the biliary fate of embryonic hepatoblasts and mature hepatocytes and the role played by Notch2
|Jeliazkova P,Jörs S,Lee M,Zimber-Strobl U,Ferrer J,Schmid RM,Siveke JT,Geisler F||Hepatology (Baltimore, Md.) (57:2469)||2013|
Expression of underglycosylated MUC1 antigen in cancerous and adjacent normal breast tissues.
MA5-11202 was used in immunohistochemistry to study the potential diagnostic value of underglycosylated MUC1 antigen in breast cancer
|Ghosh SK,Pantazopoulos P,Medarova Z,Moore A||Clinical breast cancer (13:109)||2013|
A novel anti-MUC1 antibody against the MUC1 cytoplasmic tail domain: use in sensitive identification of poorly differentiated cells in adenocarcinoma of the stomach.
MA5-11202 was used in immunohistochemistry to study the value of a novel monoclonal antibody recognizing the cytoplasmic tail of MUC1 for identifying isolated cancer cells in patients with adenocarcinoma of the stomach
|Yonezawa S,Kitajima S,Higashi M,Osako M,Horinouchi M,Yokoyama S,Kitamoto S,Yamada N,Tamura Y,Shimizu T,Tabata M,Goto M||Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (15:370)||2012|
A mouse model for monitoring islet cell genesis and developing therapies for diabetes.
MA5-11202 was used in immunohistochemistry to develop a mouse model for monitoring islet cell genesis and developing therapies for diabetes
|Shimajiri Y,Kosaka Y,Scheel DW,Lynn FC,Kishimoto N,Wang J,Zhao S,German MS||Disease models & mechanisms (4:268)||2011|
MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression.
MA5-11202 was used in immunohistochemistry to examine the therapeutic significance of MUC1 in clear renal cell carcinoma
|Aubert S,Fauquette V,Hémon B,Lepoivre R,Briez N,Bernard D,Van Seuningen I,Leroy X,Perrais M||Cancer research (69:5707)||2009|
Diagnostic value of mucins (MUC1, MUC2 and MUC5AC) expression profile in endoscopic ultrasound-guided fine-needle aspiration specimens of the pancreas.
MA5-11202 was used in immunohistochemistry to investigate the expression profiles of mucins in endoscopic ultrasound-guided fine-needle aspiration specimens of the pancreas
|Wang Y,Gao J,Li Z,Jin Z,Gong Y,Man X||International journal of cancer (121:2716)||2007|
Multiple tumor types may originate from bone marrow-derived cells.
MA5-11202 was used in immunohistochemistry to examine the role of bone marrow-derived cells in human tumorigenesis
|Liu C,Chen Z,Chen Z,Zhang T,Lu Y||Neoplasia (New York, N.Y.) (8:716)||2006|
MUC1-C nuclear localization drives invasiveness of renal cancer cells through a sheddase/gamma secretase dependent pathway.
MA5-11202 was used in immunohistochemistry and western blot to study the role of ADAM10, ADAM17 and gamma-secretase in the mechanism by which nuclear MUC1-C drives renal cancer cell invasion
|Bouillez A,Gnemmi V,Gaudelot K,Hémon B,Ringot B,Pottier N,Glowacki F,Butruille C,Cauffiez C,Hamdane M,Sergeant N,Van Seuningen I,Leroy X,Aubert S,Perrais M||Oncotarget (5:754)||2014|
MUC1 in macrophage: contributions to cigarette smoke-induced lung cancer.
MA5-11202 was used in western blot to study cigarette smoke-induced lung cancer and the role played by MUC1 expression in macrophages
|Xu X,Padilla MT,Li B,Wells A,Kato K,Tellez C,Belinsky SA,Kim KC,Lin Y||Cancer research (74:460)||2014|
MUC1 enhances hypoxia-driven angiogenesis through the regulation of multiple proangiogenic factors.
MA5-11202 was used in ChIP assay and western blot to study the mechanisms by which MUC1 promotes angiogenesis in response to hypoxia
|Kitamoto S,Yokoyama S,Higashi M,Yamada N,Takao S,Yonezawa S||Oncogene (32:4614)||2013|
Lung cancer with loss of BRG1/BRM, shows epithelial mesenchymal transition phenotype and distinct histologic and genetic features.
MA5-11202 was used in western blot to investigate epithelial-to-mesenchymal transition and the progression of lung adenocarcinomas in patients displaying loss of BRG1 and BRM
|Matsubara D,Kishaba Y,Ishikawa S,Sakatani T,Oguni S,Tamura T,Hoshino H,Sugiyama Y,Endo S,Murakami Y,Aburatani H,Fukayama M,Niki T||Cancer science (104:266)||2013|
Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation.
MA5-11202 was used in western blot to examine the anti-tumor potential of BCR-ABL disruption and secondary leukemia-specific pathway inhibitors
|Woessner DW,Lim CS||Molecular pharmaceutics (10:270)||2013|
Intrinsic mitochondrial membrane potential and associated tumor phenotype are independent of MUC1 over-expression.
MA5-11202 was used in western blot to study whether intrinsic mitochondrial membrane potential and associated tumorigenic phenotypes are linked to MUC1 expression
|Houston MA,Augenlicht LH,Heerdt BG||PloS one (6:null)||2011|
MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells.
MA5-11202 was used in western blot to study the role of MUC1-C oncoprotein in terminal differentiation of acute myelogenous leukemia cells
|Yin L,Wu Z,Avigan D,Rosenblatt J,Stone R,Kharbanda S,Kufe D||Blood (117:4863)||2011|
Nm23-h1 indirectly promotes the survival of acute myeloid leukemia blast cells by binding to more mature components of the leukemic clone.
MA5-11202 was used in western blot to study the involvement of Nm23-h1 in the tumorigeneis of acute myeloid leukemia
|Lilly AJ,Khanim FL,Hayden RE,Luong QT,Drayson MT,Bunce CM||Cancer research (71:1177)||2011|
Hypoxia enhances MUC1 expression in a lung adenocarcinoma cell line.
MA5-11202 was used in western blot to study the mechanism by which hypoxia induces MUC1 expression in a lung adenocarcinoma cell line
|Mikami Y,Hisatsune A,Tashiro T,Isohama Y,Katsuki H||Biochemical and biophysical research communications (379:1060)||2009|
A minimal fragment of MUC1 mediates growth of cancer cells.
MA5-11202 was used in western blot to examine the cleavage of mucin and its role in tumorigenesis
|Mahanta S,Fessler SP,Park J,Bamdad C||PloS one (3:null)||2008|
Dendritic cells induce MUC1 expression and polarization on human T cells by an IL-7-dependent mechanism.
MA5-11202 was used in western blot to study the role of IL-7 in the induction of MUC1 expression and T cell polarization by dendritic cells
|Vasir B,Avigan D,Wu Z,Crawford K,Turnquist S,Ren J,Kufe D||Journal of immunology (Baltimore, Md. : 1950) (174:2376)||2005|
MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress.
MA5-11202 was used in western blot to study the role of the MUC1 oncoprotein in activating FOXO3a in a survival response to oxidative stress
|Yin L,Huang L,Kufe D||The Journal of biological chemistry (279:45721)||2004|
MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells.
MA5-11202 was used in immunoprecipitation to study the activation of the FLT3 receptor by the MUC1-C oncoprotein in acute myeloid leukemia and the underlying mechanism
|Liu S,Yin L,Stroopinsky D,Rajabi H,Puissant A,Stegmaier K,Avigan D,Kharbanda S,Kufe D,Stone R||Blood (123:734)||2014|
Expression of human full-length MUC1 inhibits the proliferation and migration of a B16 mouse melanoma cell line.
MA5-11202 was used in immunoprecipitation to study the mechanisms by which expression of full length human MUC1 by the murine B16 melanoma cell inhibits its proliferation and invasiveness
|Wang F,Li Q,Ni W,Fang F,Sun X,Xie F,Wang J,Wang F,Gao S,Tai G||Oncology reports (30:260)||2013|
MUC1-C oncoprotein regulates glycolysis and pyruvate kinase M2 activity in cancer cells.
MA5-11202 was used in immunoprecipitation to study the role of MUC1-C oncoprotein in regulating glycolysis and pyruvate kinase M2 activity in cancer cells
|Kosugi M,Ahmad R,Alam M,Uchida Y,Kufe D||PloS one (6:null)||2011|
Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer.
MA5-11202 was used in immunoprecipitation and western blot to study the coexpression of the MUC1 oncoprotein and STAT1 pathways and poor prognosis in human breast cancer
|Khodarev N,Ahmad R,Rajabi H,Pitroda S,Kufe T,McClary C,Joshi MD,MacDermed D,Weichselbaum R,Kufe D||Oncogene (29:920)||2010|
Efficient generation of lung and airway epithelial cells from human pluripotent stem cells.
MA5-11202 was used in immunocytochemistry to develop a protocol for the efficient generation of airway and lung epithelial cells from human pluripotent stem cells
|Huang SX,Islam MN,O'Neill J,Hu Z,Yang YG,Chen YW,Mumau M,Green MD,Vunjak-Novakovic G,Bhattacharya J,Snoeck HW||Nature biotechnology (32:84)||2014|
Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein.
MA5-11202 was used in immunocytochemistry and western blot to study the inhibition of MUC1-C oncogene expression by blockade of eIF4A RNA helicase activity and the significance for breast cancer therapy
|Jin C,Rajabi H,Rodrigo CM,Porco JA,Kufe D||Oncogene (32:2179)||2013|
Role of the ductal transcription factors HNF6 and Sox9 in pancreatic acinar-to-ductal metaplasia.
MA5-11202 was used in immunocytochemistry to study pancreatic acinar-to-ductal metaplasia and the role played by the HNF6 and Sox9 transcription factors
|Prévot PP,Simion A,Grimont A,Colletti M,Khalaileh A,Van den Steen G,Sempoux C,Xu X,Roelants V,Hald J,Bertrand L,Heimberg H,Konieczny SF,Dor Y,Lemaigre FP,Jacquemin P||Gut (61:1723)||2012|
Localization of putative stem cells and four cell populations with different differentiation degree in mouse mammary anlagen.
MA5-11202 was used in immunocytochemistry to study the precise localization of putative stem cells and other cells within the embryonic mammary gland
|Han J,Cao S,Jin H,Liu Y,Wang M,Song J,Li N||Histochemistry and cell biology (126:35)||2006|
breast carcinoma-associated antigen DF3; cancer antigen 15-3; carcinoma-associated mucin; CD227; DF3 antigen; EMA; episialin; Epithelial Membrane Antigen; H23 antigen; KL-6; krebs von den Lungen-6; MAM6; Medullary cystic kidney disease, autosomal dominant; MUC-1/SEC; MUC-1/X; MUC1/ZD; mucin 1, transmembrane; mucin-1; peanut-reactive urinary mucin; PEM; polymorphic epithelial mucin; PUM; tumor associated epithelial mucin; tumor-associated epithelial membrane antigen
ADMCKD; ADMCKD1; CA 15-3; CD227; EMA; H23AG; KL-6; MAM6; MCD; MCKD; MCKD1; MUC-1; MUC-1/SEC; MUC-1/X; MUC1; MUC1/ZD; PEM; PEMT; PUM